Clinical trial · Interventional
Prostatic Artery Embolization in Advanced Prostate Cancer
Prostatic Artery Embolization (PAE) in Patients With Advanced Prostate Cancer: A Pilot Study.
NCT03457805CI-TRIAL-00049606unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study assessing efficacy and safety in patients with advanced prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Outlet Obstruction | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostatic Artery Embolization | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Prostatic Artery Embolization (PAE)
- description
- PAE performed under local anesthesia using officially approved microspheres.
- interventionNames
- Device: Prostatic Artery Embolization
Primary outcomes (1)
- measure
- Reduction of Lower Urinary Tract Symptoms
- timeFrame
- Baseline and 12 weeks
- description
- Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms))
Secondary outcomes (34)
- measure
- Reduction of Lower Urinary Tract Symptoms
- timeFrame
- Baseline and 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria * Advanced PCA (i.e., locally advanced, metastatic, combination of both. This includes T3-4, any T in case of N1 and any T in case of M1a/b/c) * PAE is indicated for the treatment of Lower urinary tract symptoms like bladder outlet obstruction or recurrent prostatic bleeding. * IPSS at baseline ≥ 8 * Witten informed consent Exclusion Criteria: * Curative treatment of PCA intended * Contraindications for MRI * Renal impairment (GFR \< 30ml/min) * Allergy to i.v. contrast medium * Vascular conditions that seem to make successful PAE impossible (e.g. severe atherosclerosis, severe tortuosity in the aortic bifurcation or internal iliac vessels) * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Drug-treatments for advanced prostate cancer (e.g., hormonal therapy or chemotherapy) established within 30 days prior to PAE.
References
Publications (1)
- DERIVEDBurkhardt O, Abt D, Hechelhammer L, Kim O, Omlin A, Schmid HP, Engeler D, Zumstein V, Mullhaupt G. Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study. Cardiovasc Intervent Radiol. 2024 Jun;47(6):771-782. doi: 10.1007/s00270-024-03679-z. Epub 2024 Feb 28. PMID 38416176